Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "FDC"

25 News Found

Sigachi Industries receives CEP for Metformin Hydrochloride from EDQM
News | May 08, 2025

Sigachi Industries receives CEP for Metformin Hydrochloride from EDQM

The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets


Glenmark Pharma launches Empagliflozin and its fixed-drug combinations in India
News | March 13, 2025

Glenmark Pharma launches Empagliflozin and its fixed-drug combinations in India

Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M


Cadila launches Rs. 200 crore API facility in Dahej
News | November 30, 2023

Cadila launches Rs. 200 crore API facility in Dahej

Equipped with most advanced Distributed Control System (DCS) automation technology, the facility has been set up with an investment of Rs. 200 crore


Lupin launches Vilfuro-G for COPD Management in India
News | November 23, 2023

Lupin launches Vilfuro-G for COPD Management in India

Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide


USFDA delegation visits Amneal Pharmaceutical facility in Matoda
News | September 02, 2023

USFDA delegation visits Amneal Pharmaceutical facility in Matoda

Amneal’s site in Matoda is one of the company’s 12 pharmaceutical manufacturing facilities


Par Drugs and Chemicals receives WHO-GMP certificate
News | March 06, 2023

Par Drugs and Chemicals receives WHO-GMP certificate

The audit was commenced for newly renovated manufacturing Block 1, Block 2, and Block 3


Jubilant’s Radiopharma business receives NDA approval for Technetium Mertiatide Injection
Drug Approval | February 02, 2023

Jubilant’s Radiopharma business receives NDA approval for Technetium Mertiatide Injection

The Tc 99m Mertiatide Injection is used in the diagnosis of congenital and acquired renal abnormalities


Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma
News | January 06, 2023

Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma

The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”


Glenmark launches Zita D for adults with Type 2 diabetes having comorbidities
News | October 21, 2022

Glenmark launches Zita D for adults with Type 2 diabetes having comorbidities

A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities


Cadila Pharma launches formulation development lab
News | June 21, 2022

Cadila Pharma launches formulation development lab

The ground floor of the formulation development laboratory is focused on solid orals, the first floor on injections, and the second floor houses the analytical lab